Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
In the first randomized comparison of pirtobrutinib versus ibrutinib in BTKi‑naïve CLL/SLL (N=662), pirtobrutinib met noninferiority for overall response and showed favorable early PFS trends and lower rates of atrial fibrillation and hyper
This article explores genomic factors influencing response and resistance to pirtobrutinib, a reversible BTK inhibitor, in relapsed/refractory CLL patients previously treated with covalent BTK inhibitors, highlighting clonal mutation dynami
Pirtobrutinib significantly improves progression-free survival and tolerability over standard regimens in covalent BTK inhibitor-pretreated CLL/SLL, offering a promising new option for this challenging population.